Factors related to therapeutic efficacy in adoptive chemoimmunotherapy of a Friend virus-induced lymphoma.
D000818:Animals; D000917:Antibody Formation; D000951:Antigens, Neoplasm / Q000008:administration & dosage*; D000956:Antigens, Viral; D002478:Cells, Cultured; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D005622:Friend murine leukemia virus; D007110:Immunity, Active; D007114:Immunization; D007115:Immunization Schedule; D007167:Immunotherapy; D017710:Lymphocyte Transfusion; D008214:Lymphocytes / Q000276:immunology; D008221:Lymphoid Tissue / Q000276:immunology; D008223:Lymphoma / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008979:Moloney murine leukemia virus; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000276:immunology / Q000628:therapy; D012513:Sarcoma, Experimental / Q000276:immunology; D013154:Spleen / Q000276:immunology; D014184:Transplantation, Homologous
D000951:Antigens, Neoplasm; D000956:Antigens, Viral; D003520:Cyclophosphamide